Rexgenero

15 articles with Rexgenero

• Rexgenero Appoints Sadia L’Baouch as Chief Manufacturing Officer

  12/7/2020

  Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischemia, announces the appointment of Sadia L’Baouch as Chief Manufacturing Officer, effective 4 January 2021.

• Rexgenero Announces Positive Outcome of Independent Data Monitoring Committee Meeting for Phase III Trial for Diabetic Patients with Critical Limb-Threatening Ischaemia

  10/26/2020

  REX-001 is an autologous cell-based product intended to treat critical limb-threatening ischaemia in diabetic patients

• Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer

  7/2/2020

  Rexgenero announces that Dr Gilbert Wagener has joined the Company as Senior Vice President and Chief Medical Officer.

• Rexgenero Appoints Huw Jones as a Non-executive Director

  2/12/2020

  Rexgenero announces that Dr Huw Jones has joined the Company’s Board as a non-executive director, and will chair the Company’s remuneration committee.

• Rexgenero Appoints David Horn Solomon as Chairman

  2/10/2020

  Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia, announces that Dr. David Horn Solomon has been appointed to the role of Chairman, effective immediately.

• 

  BioSpace Global Roundup, Aug. 22

  8/22/2019

  Companies from across the globe provide updates on their business and pipelines.

• Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies

  8/21/2019

  Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.

• First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava

  5/29/2019

  Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting

• Rexgenero Successfully Expands Manufacturing of REX-001 through Partnership with German Red Cross Blood Donor Service

  5/28/2019

  Enables new sites to participate in the European Phase III SALAMANDER trials

• Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia

  4/24/2019

  At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona

• EMA Grants Rexgenero's Lead Product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data

  1/30/2018

  The EMA certification paves the way for the MAA of its lead product REX-001, a novel cell therapy currently in a Phase III programme for the treatment of CLI. 

• Rexgenero Secures Innovate UK Grant

  1/23/2018

  The grant is a consortium between the Cell and Gene Therapy Catapult, TrakCel and Fisher Bioservices.

• Consortium Including Trakcel Awarded GBP 1.4 Million From Innovate UK for Commercialisation of Rexgenero Cell Therapy

  1/23/2018

  The project will focus on and design a cost effective commercial manufacturing strategy for Rexgenero's novel autologous cell therapy REX-001.

• Rexgenero Announces the Appointment of Sam MacHour to its Scientific Advisory Board

  11/13/2017

  Rexgenero is pleased to announce today the appointment of Sam MacHour to its SAB.

• Rexgenero Announces Formation Of Scientific Advisory Board

  1/5/2017